 | • レポートコード：D0JU09126 • 出版社/出版日：Transparency Market Research / 2020年1月22日 • レポート形態：英文、PDF、225ページ • 納品方法：Eメール • 産業分類：製薬 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、網膜障害治療の世界市場について調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場動向、市場概要、疾患適応症（黄斑変性症、糖尿病性網膜症、糖尿病性黄斑浮腫、その他）分析、治療クラス別（抗VEGF剤、その他（抗炎症薬、その他））分析、剤形別（ジェル、目薬、カプセル＆タブレット、点眼薬、軟膏）分析、流通経路別（病院薬局、小売薬局、オンライン販売）分析、地域別分析、競争分析などの構成でお届けいたします。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場動向 ・市場概要 ・網膜障害治療の世界市場：疾患適応症（黄斑変性症、糖尿病性網膜症、糖尿病性黄斑浮腫、その他） ・網膜障害治療の世界市場：治療クラス別（抗VEGF剤、その他（抗炎症薬、その他）） ・網膜障害治療の世界市場：剤形別（ジェル、目薬、カプセル＆タブレット、点眼薬、軟膏） ・網膜障害治療の世界市場：流通経路別（病院薬局、小売薬局、オンライン販売） ・網膜障害治療の世界市場：地域別 ・競争分析 |
Retinal Disorder Treatment Market – Scope of the Report
TMR’s report on the global retinal disorder treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators for the market during the forecast period from 2019 to 2027. The report provides revenue of the retinal disorder treatment market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the retinal disorder treatment market from 2019 to 2027.
The report is prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Extensive secondary research involved reaching out to key players’ product literature, annual reports, press releases, and relevant documents to understand the retinal disorder treatment market.
Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the retinal disorder treatment market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Moreover, the report sheds light on changing competitive dynamics in the retinal disorder treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the retinal disorder treatment market.
The report delves into the competitive landscape of the retinal disorder treatment market. Key players operating in the retinal disorder treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the retinal disorder treatment market that are profiled in this report.
Key Questions Answered in TMR’s Report on Retinal Disorder Treatment Market
What is the sales/revenue generated by retinal disorder treatment products across all regions during the forecast period?
What are the opportunities in the retinal disorder treatment market?
What are the major drivers, restraints, opportunities, and threats in the market?
In which region is the retinal disorder treatment market set to expand at the fastest CAGR during the forecast period?
Which product segment is expected to generate the highest revenue globally in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Retinal Disorder Treatment Market – Research Objectives and Research Approach
The comprehensive report on the retinal disorder treatment market begins with an overview, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the retinal disorder treatment market, in terms of disease indication, therapeutic class, dosage form, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2027 has also been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the retinal disorder treatment market.
レポート目次1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology
3. Executive Summary
3.1. Global Retinal Disorder Treatment Market Snapshot
4. Market Overview
4.1. Product Overview
4.2. Key Industry Events
4.3. Market Dynamics
4.3.1. Drivers and Restraints Snapshot Analysis
4.3.2. Drivers
4.3.3. Restraints
4.3.4. Opportunities
4.4. Global Retinal Disorder Treatment Market Revenue Projection
4.5. Global Retinal Disorder Treatment Market Outlook
5. Market Outlook
5.1. Clinical Trial Analysis
5.2. Regulatory Scenario
5.3. Pipeline Analysis
5.4. Key Mergers & Acquisitions
5.5. Reimbursement Scenario
6. Global Retinal Disorder Treatment Market Analysis, by Disease Indication
6.1. Introduction
6.2. Global Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Disease Indication
6.3. Global Retinal Disorder Treatment Market Forecast, by Disease Indication
6.3.1. Macular Degeneration
6.3.1.1. Dry Macular Degeneration
6.3.1.2. Wet Macular Degeneration
6.3.2. Diabetic Retinopathy
6.3.3. Diabetic Macular Edema
6.3.4. Others (Retinal Vein Occlusion, etc.)
7. Global Retinal Disorder Treatment Market Analysis, by Therapeutic Class
7.1. Introduction
7.2. North America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Therapeutic Class
7.3. North America Retinal Disorder Treatment Market Forecast, by Therapeutic Class
7.3.1. Anti-VEGF Agents
7.3.2. Others (Anti-inflammatory Drugs, etc.)
8. Global Retinal Disorder Treatment Market Analysis, by Dosage Form
8.1. Introduction
8.2. Global Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Dosage Form
8.3. Global Retinal Disorder Treatment Market Forecast, by Dosage Form
8.3.1. Gels
8.3.2. Eye Solutions
8.3.3. Capsules & Tablets
8.3.4. Eye Drops
8.3.5. Ointments
8.4. Global Retinal Disorder Treatment Market Analysis, by Dosage Form
9. Global Retinal Disorder Treatment Market Analysis, by Distribution Channel
9.1. Introduction
9.2. Global Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
9.3. Global Retinal Disorder Treatment Market Forecast, by Distribution Channel
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Sales
9.4. Global Retinal Disorder Treatment Market Analysis, by Distribution Channel
10. Global Retinal Disorder Treatment Market Analysis, by Region
10.1. Global Retinal Disorder Treatment Market Scenario, by Country
10.2. Global Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Region
10.3. Global Retinal Disorder Treatment Market Forecast, by Region
10.3.1. North America
10.3.2. Europe
10.3.3. Asia Pacific
10.3.4. Latin America
10.3.5. Middle East & Africa
11. North America Retinal Disorder Treatment Market Analysis
11.1. Key Findings
11.2. North America Retinal Disorder Treatment Market Overview
11.3. North America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Country
11.4. North America Retinal Disorder Treatment Market Forecast, by Country
11.4.1. U.S.
11.4.2. Canada
11.5. North America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Disease Indication
11.6. North America Retinal Disorder Treatment Market Forecast, by Disease Indication
11.6.1. Macular Degeneration
11.6.1.1. Dry Macular Degeneration
11.6.1.2. Wet Macular Degeneration
11.6.2. Diabetic Retinopathy
11.6.3. Diabetic Macular Edema
11.6.4. Others (Retinal Vein Occlusion, etc.)
11.7. North America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Therapeutic Class
11.8. North America Retinal Disorder Treatment Market Forecast, by Therapeutic Class
11.8.1. Anti-VEGF Agents
11.8.2. Others (Anti-inflammatory Drugs, etc.)
11.9. North America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Dosage Form
11.10. North America Retinal Disorder Treatment Market Forecast, by Dosage Form
11.10.1. Gels
11.10.2. Eye Solutions
11.10.3. Capsules & Tablets
11.10.4. Eye Drops
11.10.5. Ointments
11.11. North America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
11.12. North America Retinal Disorder Treatment Market Forecast, by Distribution Channel
11.12.1. Hospital Pharmacies
11.12.2. Retail Pharmacies
11.12.3. Online Sales
12. Europe Retinal Disorder Treatment Market Analysis
12.1. Key Findings
12.2. Europe Retinal Disorder Treatment Market Overview
12.3. Europe Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.4. Europe Retinal Disorder Treatment Market Forecast, by Country/Sub-region
12.4.1. Germany
12.4.2. France
12.4.3. U.K.
12.4.4. Italy
12.4.5. Spain
12.4.6. Rest of Europe
12.5. Europe Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Disease Indication
12.6. Europe Retinal Disorder Treatment Market Forecast, by Disease Indication
12.6.1. Macular Degeneration
12.6.1.1. Dry Macular Degeneration
12.6.1.2. Wet Macular Degeneration
12.6.2. Diabetic Retinopathy
12.6.3. Diabetic Macular Edema
12.6.4. Others (Retinal Vein Occlusion, etc.)
12.7. Europe Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Therapeutic Class
12.8. Europe Retinal Disorder Treatment Market Forecast, by Therapeutic Class
12.8.1. Anti-VEGF Agents
12.8.2. Others (Anti-inflammatory Drugs, etc.)
12.9. Europe Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Dosage Form
12.10. Europe Retinal Disorder Treatment Market Forecast, by Dosage Form
12.10.1. Gels
12.10.2. Eye Solutions
12.10.3. Capsules & Tablets
12.10.4. Eye Drops
12.10.5. Ointments
12.11. Europe Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
12.12. Europe Retinal Disorder Treatment Market Forecast, by Distribution Channel
12.12.1. Hospital Pharmacies
12.12.2. Retail Pharmacies
12.12.3. Online Sales
13. Asia Pacific Retinal Disorder Treatment Market Analysis
13.1. Key Findings
13.2. Asia Pacific Retinal Disorder Treatment Market Overview
13.3. Asia Pacific Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.4. Asia Pacific Retinal Disorder Treatment Market Forecast, by Country/Sub-region
13.4.1. Japan
13.4.2. China
13.4.3. India
13.4.4. Australia & New Zealand
13.4.5. Rest of Asia Pacific
13.5. Asia Pacific Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Disease Indication
13.6. Asia Pacific Retinal Disorder Treatment Market Forecast, by Disease Indication
13.6.1. Macular Degeneration
13.6.1.1. Dry Macular Degeneration
13.6.1.2. Wet Macular Degeneration
13.6.2. Diabetic Retinopathy
13.6.3. Diabetic Macular Edema
13.6.4. Others (Retinal Vein Occlusion, etc.)
13.7. Asia Pacific Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Therapeutic Class
13.8. Asia Pacific Retinal Disorder Treatment Market Forecast, by Therapeutic Class
13.8.1. Anti-VEGF Agents
13.8.2. Others (Anti-inflammatory Drugs, etc.)
13.9. Asia Pacific Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Dosage Form
13.10. Asia Pacific Retinal Disorder Treatment Market Forecast, by Dosage Form
13.10.1. Gels
13.10.2. Eye Solutions
13.10.3. Capsules & Tablets
13.10.4. Eye Drops
13.10.5. Ointments
13.11. Asia Pacific Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
13.12. Asia Pacific Retinal Disorder Treatment Market Forecast, by Distribution Channel
13.12.1. Hospital Pharmacies
13.12.2. Retail Pharmacies
13.12.3. Online Sales
14. Latin America Retinal Disorder Treatment Market Analysis
14.1. Key Findings
14.2. Latin America Retinal Disorder Treatment Market Overview
14.3. Latin America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.4. Latin America Retinal Disorder Treatment Market Forecast, by Country/Sub-region
14.4.1. Brazil
14.4.2. Mexico
14.4.3. Rest of Latin America
14.5. Latin America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Disease Indication
14.6. Latin America Retinal Disorder Treatment Market Forecast, by Disease Indication
14.6.1. Macular Degeneration
14.6.1.1. Dry Macular Degeneration
14.6.1.2. Wet Macular Degeneration
14.6.2. Diabetic Retinopathy
14.6.3. Diabetic Macular Edema
14.6.4. Others (Retinal Vein Occlusion, etc.)
14.7. Latin America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Therapeutic Class
14.8. Latin America Retinal Disorder Treatment Market Forecast, by Therapeutic Class
14.8.1. Anti-VEGF Agents
14.8.2. Others (Anti-inflammatory Drugs, etc.)
14.9. Latin America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Dosage Form
14.10. Latin America Retinal Disorder Treatment Market Forecast, by Dosage Form
14.10.1. Gels
14.10.2. Eye Solutions
14.10.3. Capsules & Tablets
14.10.4. Eye Drops
14.10.5. Ointments
14.11. Latin America Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
14.12. Latin America Retinal Disorder Treatment Market Forecast, by Distribution Channel
14.12.1. Hospital Pharmacies
14.12.2. Retail Pharmacies
14.12.3. Online Sales
15. Middle East & Africa Retinal Disorder Treatment Market Analysis
15.1. Key Findings
15.2. Middle East & Africa Retinal Disorder Treatment Market Overview
15.3. Middle East & Africa Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
15.4. Middle East & Africa Retinal Disorder Treatment Market Forecast, by Country/Sub-region
15.4.1. GCC Countries
15.4.2. South Africa
15.4.3. Rest of Middle East & Africa
15.5. Middle East & Africa Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Disease Indication
15.6. Middle East & Africa Retinal Disorder Treatment Market Forecast, by Disease Indication
15.6.1. Macular Degeneration
15.6.1.1. Dry Macular Degeneration
15.6.1.2. Wet Macular Degeneration
15.6.2. Diabetic Retinopathy
15.6.3. Diabetic Macular Edema
15.6.4. Others (Retinal Vein Occlusion, etc.)
15.7. Middle East & Africa Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Therapeutic Class
15.8. Middle East & Africa Retinal Disorder Treatment Market Forecast, by Therapeutic Class
15.8.1. Anti-VEGF Agents
15.8.2. Others (Anti-inflammatory Drugs, etc.)
15.9. Middle East & Africa Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Dosage Form
15.10. Middle East & Africa Retinal Disorder Treatment Market Forecast, by Dosage Form
15.10.1. Gels
15.10.2. Eye Solutions
15.10.3. Capsules & Tablets
15.10.4. Eye Drops
15.10.5. Ointments
15.11. Middle East & Africa Retinal Disorder Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
15.12. Middle East & Africa Retinal Disorder Treatment Market Forecast, by Distribution Channel
15.12.1. Hospital Pharmacies
15.12.2. Retail Pharmacies
15.12.3. Online Sales
16. Competition Analysis
16.1. Global Retinal Disorder Treatment Market Share Analysis, by Company
16.2. Competition Matrix
16.3. Company Profile
16.3.1. Santen Pharmaceutical Co., Ltd.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Regeneron Pharmaceuticals, Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Financial Overview
16.3.2.3. Product Portfolio
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. F. Hoffmann-La Roche Ltd.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Financial Overview
16.3.3.3. Product Portfolio
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Pfizer, Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Financial Overview
16.3.4.3. Product Portfolio
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Allergan plc
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Financial Overview
16.3.5.3. Product Portfolio
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Shire (Takeda Pharmaceutical Company Limited)
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Financial Overview
16.3.6.3. Product Portfolio
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Bayer AG
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Financial Overview
16.3.7.3. Product Portfolio
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Graybug Vision, Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Financial Overview
16.3.8.3. Product Portfolio
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Novartis AG
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Financial Overview
16.3.9.3. Product Portfolio
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Acucela Inc. (Kubota Pharmaceutical Holdings Co., Ltd.)
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Financial Overview
16.3.10.3. Product Portfolio
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
List of TablesTable 01: Global Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027
Table 02: Global Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Macular Degeneration, 2017–2027
Table 03: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027
Table 04: Global Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 05: Global Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 06: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 07: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027
Table 08: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Macular Degeneration, 2017–2027
Table 09: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027
Table 10: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027
Table 11: North America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 12: Europe Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 13: Europe Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027
Table 14: Europe Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Macular Degeneration, 2017–2027
Table 15: Europe Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027
Table 16: Europe Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027
Table 17: Europe Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 18: Asia Pacific Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 19: Asia Pacific Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027
Table 20: Asia Pacific Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Macular Degeneration, 2017–2027
Table 21: Asia Pacific Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027
Table 22: Asia Pacific Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027
Table 23: Asia Pacific Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 24: Latin America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 25: Latin America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027
Table 26: Latin America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Macular Degeneration, 2017–2027
Table 27: Latin America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027
Table 28: Latin America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027
Table 29: Latin America Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 30: Middle East & Africa Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 31: Middle East & Africa Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027
Table 32: Middle East & Africa Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Macular Degeneration, 2017–2027
Table 33: Middle East & Africa Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2027
Table 34: Middle East & Africa Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2027
Table 35: Middle East & Africa Retinal Disorder Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027